Hypothalamic monoamine metabolism in mice: evaluation of drug challenges and neurotoxic insult.
Hypothalamic monoamine metabolism was evaluated in male and female mice that were administered monosodium glutamate (MSG, 4 mg/g) on postnatal day 4. Hypothalamic dopamine (DA) content was reduced approximately by 22% across all experiments and pituitary DA content was also significantly decreased. Despite reductions in hypothalamic DA levels, MSG-treated mice did not exhibit significant reductions in the levels of the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Hypothalamic monoamine and metabolite profiles in MSG-treated and control mice were examined after the administration of pargyline (PAR), alpha-methyl-p-tyrosine (MPT) or reserpine (RES). DA turnover as indexed by PAR and MPT techniques were not as conclusive as the metabolite measures in suggesting an accelerated DA utilization. MSG-treated mice were more resistant to the DA-depleting actions of reserpine than were the controls. No alterations were found in hypothalamic norepinephrine metabolism in MSG-treated mice, however, after drug challenges, alterations were found in serotonin metabolism. These results indicate the extent and nature of the changes that occur in hypothalamic monoamine metabolism after neonatal MSG treatment. The DA neurons that survive MSG treatment appear to exhibit neurochemical characteristics dissimilar to those of tuberoinfundibular DA neurons. Additionally, the neuropharmacological actions of MPT, PAR and RES are discussed as they relate to hypothalamine monoamine metabolism in the mouse.
Dawson
R
R
Callahan
M F
MF
Annau
Z
Z
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D004298:Dopamine / Q000096:biosynthesis / Q000378:metabolism*; D005260:Female; D005971:Glutamates / Q000633:toxicity*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D008781:Methyltyrosines / Q000494:pharmacology; D051379:Mice; D009638:Norepinephrine / Q000378:metabolism; D009765:Obesity / Q000139:chemically induced; D010293:Pargyline / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D012970:Sodium Glutamate / Q000633:toxicity*; D019805:alpha-Methyltyrosine
D005971:Glutamates; D008781:Methyltyrosines; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D019805:alpha-Methyltyrosine; D012110:Reserpine; D010293:Pargyline; D004298:Dopamine; D012970:Sodium Glutamate; D009638:Norepinephrine; D006719:Homovanillic Acid